Nanjing Medlander Medical Technology Co. Ltd. A (688273) - Net Assets
Based on the latest financial reports, Nanjing Medlander Medical Technology Co. Ltd. A (688273) has net assets worth CN¥1.36 Billion CNY (≈ $199.59 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.52 Billion ≈ $222.85 Million USD) and total liabilities (CN¥158.97 Million ≈ $23.26 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Nanjing Medlander Medical Technology Co. (688273) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.36 Billion |
| % of Total Assets | 89.56% |
| Annual Growth Rate | 52.74% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 110.8 |
Nanjing Medlander Medical Technology Co. Ltd. A - Net Assets Trend (2020–2024)
This chart illustrates how Nanjing Medlander Medical Technology Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See Nanjing Medlander Medical Technology Co. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Nanjing Medlander Medical Technology Co. Ltd. A (2020–2024)
The table below shows the annual net assets of Nanjing Medlander Medical Technology Co. Ltd. A from 2020 to 2024. For live valuation and market cap data, see market cap of Nanjing Medlander Medical Technology Co..
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.35 Billion ≈ $197.10 Million |
-2.06% |
| 2023-12-31 | CN¥1.38 Billion ≈ $201.25 Million |
+0.39% |
| 2022-12-31 | CN¥1.37 Billion ≈ $200.47 Million |
+267.54% |
| 2021-12-31 | CN¥372.74 Million ≈ $54.54 Million |
+50.62% |
| 2020-12-31 | CN¥247.47 Million ≈ $36.21 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nanjing Medlander Medical Technology Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 226.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥238.68 Million | 18.19% |
| Other Components | CN¥1.07 Billion | 81.81% |
| Total Equity | CN¥1.31 Billion | 100.00% |
Nanjing Medlander Medical Technology Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Nanjing Medlander Medical Technology Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WA1 Resources Ltd
AU:WA1
|
$646.50 Million |
|
Shanghai Sheng Jian Environment Technology Co Ltd
SHG:603324
|
$646.58 Million |
|
Princess Private Equity Holding Ltd
LSE:PEY
|
$646.59 Million |
|
Zhejiang Meida Industrial Co Ltd
SHE:002677
|
$646.64 Million |
|
Hanilcmt Co Ltd
KO:300720
|
$646.33 Million |
|
Merida Industry Co Ltd
TW:9914
|
$646.19 Million |
|
Zhejiang Unifull Industrial Fibre Co Ltd
SHE:002427
|
$646.02 Million |
|
Tyntek Corp
TW:2426
|
$645.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanjing Medlander Medical Technology Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,345,778,874 to 1,312,201,920, a change of -33,576,954 (-2.5%).
- Net income of 101,581,195 contributed positively to equity growth.
- Dividend payments of 98,898,003 reduced retained earnings.
- Other factors decreased equity by 36,260,146.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥101.58 Million | +7.74% |
| Dividends Paid | CN¥98.90 Million | -7.54% |
| Other Changes | CN¥-36.26 Million | -2.76% |
| Total Change | CN¥- | -2.49% |
Book Value vs Market Value Analysis
This analysis compares Nanjing Medlander Medical Technology Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.78x to 3.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥3.21 | CN¥44.18 | x |
| 2021-12-31 | CN¥4.85 | CN¥44.18 | x |
| 2022-12-31 | CN¥13.50 | CN¥44.18 | x |
| 2023-12-31 | CN¥13.37 | CN¥44.18 | x |
| 2024-12-31 | CN¥13.12 | CN¥44.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanjing Medlander Medical Technology Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.74%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 23.93%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.18x
- Recent ROE (7.74%) is below the historical average (21.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 50.72% | 36.23% | 1.00x | 1.40x | CN¥97.89 Million |
| 2021 | 32.57% | 34.65% | 0.70x | 1.34x | CN¥82.03 Million |
| 2022 | 9.01% | 32.29% | 0.25x | 1.12x | CN¥-13.33 Million |
| 2023 | 6.67% | 26.35% | 0.22x | 1.14x | CN¥-44.76 Million |
| 2024 | 7.74% | 23.93% | 0.27x | 1.18x | CN¥-29.64 Million |
Industry Comparison
This section compares Nanjing Medlander Medical Technology Co. Ltd. A's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,190,414,901
- Average return on equity (ROE) among peers: 19.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanjing Medlander Medical Technology Co. Ltd. A (688273) | CN¥1.36 Billion | 50.72% | 0.12x | $646.49 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $1.27 Billion | 23.03% | 0.13x | $386.11 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $2.13 Billion | 17.09% | 0.37x | $3.67 Billion |
| Double Medical Technology Inc (002901) | $2.59 Billion | 26.01% | 0.31x | $2.49 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $49.59 Million | 43.44% | 0.23x | $527.05 Million |
| Lepu Medical Tech Beijing (300003) | $115.51 Million | 55.06% | 0.54x | $3.17 Billion |
| INKON Life Technology Co Ltd (300143) | $785.85 Million | 7.49% | 0.06x | $790.71 Million |
| Edan Instruments Inc (300206) | $1.18 Billion | 2.94% | 0.08x | $1.13 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.50 Billion | 1.47% | 0.62x | $630.75 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.34 Billion | 5.21% | 0.24x | $444.20 Million |
| Sinocare Inc (300298) | $946.01 Million | 17.47% | 0.11x | $1.19 Billion |
About Nanjing Medlander Medical Technology Co. Ltd. A
Nanjing Medlander Medical Technology Co.,Ltd. engages in the research and development, manufacture, sale, and service of pelvic floor rehabilitation equipment and related products in China and internationally. It offers pelvic floor and obstetrics and gynecology rehabilitation, reproductive rehabilitation product, and sports rehabilitation products, as well as consumables products, such as vagina… Read more